Olaparib (re-assessment: adult patients with advanced (FIGO stages III and IV) epithelial ovarian, fallopian tube or primary peritoneal cancer, homologous recombination deficiency (HRD) positive, maintenance treatment in combination with Bevacizumab)

Subject:

• Active Substance: Olaparib
• Name: Lynparza®
• Therapeutic area: Ovarian cancer
• Pharmaceutical company: AstraZeneca GmbH

Time table:

• Start: 01.11.2022
• Final decision by G-BA: 21.04.2023

Final decision:

• Hint for a considerable additional benefit